Valsartan 40 mg

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, University of Washington

Conditions

Essential HypertensionHypertensionPulmonary Arterial HypertensionPulmonary Vascular DisorderRight Heart FailureRight Ventricular Dysfunction

Phase 2

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

CompletedNCT00425373

Novartis PharmaceuticalsEssential Hypertension

Start: 2006-11-30End: 2008-03-31Updated: 2011-04-29

Repurposing Valsartan May Protect Against Pulmonary Hypertension

RecruitingNCT06053580

University of WashingtonPulmonary Arterial Hypertension, Pulmonary Vascular Disorder, Right Heart Failure +1

Start: 2024-02-28End: 2027-07-01Target: 60Updated: 2025-03-25

Phase 3

Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension

CompletedNCT00699192

Novartis PharmaceuticalsHypertension

Start: 2008-05-31End: 2009-05-31Updated: 2011-06-06